Stock 600211 TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.
Add to a list
To use this feature you must be a member
Log inSign up

Tibet Rhodiola Pharmaceutical Holding Co. Stock

Equities

600211

CNE000000ZW7

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-14 pm EDT 		5-day change 1st Jan Change
44.49 CNY +1.74% Intraday chart for Tibet Rhodiola Pharmaceutical Holding Co. +1.18% -8.83%
Mar. 26 Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jan. 14 Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co. CI

Financials

Sales 2024 * 3.44B 475M Sales 2025 * 4.07B 562M Capitalization 11.03B 1.52B
Net income 2024 * 1.02B 142M Net income 2025 * 1.23B 169M EV / Sales 2024 * 3.21 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.71 x
P/E ratio 2024 *
10.8 x
P/E ratio 2025 *
8.99 x
Employees 601
Yield 2024 *
-
Yield 2025 *
-
Free-Float 37.89%
More Fundamentals * Assessed data

Chart Tibet Rhodiola Pharmaceutical Holding Co.

Dynamic Chart

Latest news about Tibet Rhodiola Pharmaceutical Holding Co.

Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co. CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tibet Rhodiola Pharma Unit Becomes Authorized Marketer of Heart Drug MT
Tibet Rhodiola Pharma Sees 81% Jump in 2022 Profit MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Tibet Rhodiola Pharma Wins License to Produce Chest Pain Tablets MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) added to Shanghai Stock Exchange A Share Index CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange A Share Index CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news

Quotes and Performance

1 day+1.74%
1 week+1.18%
Current month+0.68%
1 month-4.40%
3 months-3.47%
6 months-10.97%
Current year-8.83%
More quotes

Highs and lows

1 week
43.57
Extreme 43.57
45.38
1 month
43.41
Extreme 43.41
47.44
Current year
35.04
Extreme 35.04
49.61
1 year
35.04
Extreme 35.04
64.47
3 years
29.55
Extreme 29.55
73.00
5 years
20.11
Extreme 20.107
182.07
10 years
14.28
Extreme 14.2785
182.07
More quotes

Managers and Directors - Tibet Rhodiola Pharmaceutical Holding Co.

Managers TitleAgeSince
Yuan Dong Guo CEO
 Chief Executive Officer 54 -
Jun Chen DFI
 Director of Finance/CFO 46 11-12-31
Yu Cheng Zhou BRD
 Director/Board Member 42 -
Members of the board TitleAgeSince
Da Bin Chen CHM
 Chairman 68 -
Yu Cheng Zhou BRD
 Director/Board Member 42 -
Yuan Dong Guo CEO
 Chief Executive Officer 54 -
More insiders

ETFs positioned on Tibet Rhodiola Pharmaceutical Holding Co.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.25% -
More ETFs positioned on Tibet Rhodiola Pharmaceutical Holding Co.

Quotes

Date Price Change Volume
24-04-15 44.49 +1.74% 2,558,300
24-04-12 43.73 -1.00% 1,484,300
24-04-11 44.17 -0.20% 1,657,902
24-04-10 44.26 -1.43% 1,949,100
24-04-09 44.9 +2.12% 2,362,024

End-of-day quote Shanghai S.E., April 14, 2024

More quotes

Company Profile

TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.
Sector
Pharmaceuticals
Calendar
02:30am - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Ratings for Tibet Rhodiola Pharmaceutical Holding Co.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
44.49
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. Stock Tibet Rhodiola Pharmaceutical Holding Co.
-8.83% 1.5B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.79% 677B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.94% 560B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.84% 355B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.75% 319B
ABBVIE INC. Stock AbbVie Inc.
+4.32% 287B
ASTRAZENECA PLC Stock AstraZeneca PLC
+4.00% 214B
NOVARTIS AG Stock Novartis AG
+1.92% 207B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 199B
PFIZER, INC. Stock Pfizer, Inc.
-10.00% 146B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600211 Stock